PMID: 18935781
2008
Central European journal of public health
Abstract: In the group of NRTI mutations M184V (26/75; 34.6%), A62V (12/75; 16.0%) and T215Y (8/75; 10.6%), in NNRTI mutations K103N (10/75; 13.3%), G190S (6/75; 8.0%), in PI group mutations L90M (6/75; 8.0%) and M461/L (6/75; 8.0%) occurred most frequently.
HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy.
PMID: 19000027
2008
AIDS research and human retroviruses
Abstract: Of the patients who received PIs, the most common mutations were V82A/T (12%), M46I (11%), and L90M (8%).
Transmission networks of drug resistance acquired in primary/early stage HIV infection.
Result: L90M, V82I, that have limited impact on drug susceptibility and viral replicative capacity.
Result: In addition, cluster C represents an MDR transmission network, wherein all four PHIs harboured K103N and three of the four also harboured L10I, I54V, A71V, V82A/I/T, I84I/V, and L90M.
Short communication: Different mutation patterns in subtype CRF06_cpx after mother-to-child transmission.
PMID: 19032066
2008
AIDS research and human retroviruses
Abstract: Genotypic resistance tests (GRT) during follow-up showed selection of M184V/L283I in reverse transcriptase (RT) and H63Q/A71V/L90M in protease (PR).
Prevalence of resistance-associated mutations in human immunodeficiency virus type 1-positive individuals failing HAART in Rio de Janeiro, Brazil.
PMID: 19219276
2008
The Brazilian journal of infectious diseases
Abstract: The most prevalent resistance mutations were: M184V (60.7%), T215Y (49.6%) and M41L (46.7%) in the RT gene and L90M (19.6%), M46I (16.2%) and D30N (12.8%) in the PR gene.
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
PMID: 17116674
2007
Antimicrobial agents and chemotherapy
Abstract: The acquisition of the I54M, I84V, L90M, and L99F mutations resulted in multi-PI-resistant viruses, conferring 10-fold to more than 100-fold resistance.
Abstract: Within 10 to 15 weeks of serial passage, three major mutations--I54M, I82F, and L90M--arose in HIV-2 viral cultures exposed to APV, NFV, and IDV, whereas I82L was selected with TPV.
A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
Method: In addition, the model was also adjusted on use of nelfinavir at baseline and on the number of PI mutations (L10IRVF, K20RM, M36I, A71VT, G73SA, V82AFTS, L90M) found to be associated with the virological response in univariate analyses in this subset of patients.
Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients.
PMID: 17296739
2007
Antimicrobial agents and chemotherapy
Abstract: The Zephir mutation score included 12 IAS protease mutations associated with poorer virological response: L10I/F/R/V, L33F, M36I, M46I/L, I54L/M/T/V, I62V, L63P, A71I/L/V/T, G73A/C/F/T, V82A/F/S/T, I84V, L90M, and polymorphism mutations I13V, L19I, K55R, and L89M.
Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations.
Abstract: Characterization of tipranavir binding to wild-type protease, active site mutants I50V and V82F/I84V, the multidrug-resistant mutant L10I/L33I/M46I/I54V/L63I/V82A/I84V/L90M, and the tipranavir in vitro-selected mutant I13V/V32L/L33F/K45I/V82L/I84V was performed by isothermal titration calorimetry and crystallography.
Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients.
Abstract: The selection of three key resistance mutations, L90M (protease), K103N and M184V (reverse transcriptase), were measured by allele-specific real-time PCR allowing us to track minority quasispecies with a discriminative power of 0.01-0.2%.
HIV mutation literature information.
PMID: 
2008
Central European journal of public health
Browser Board
Co-occurred Entities
Filtrator
ViMRT